This HTML5 document contains 88 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n19https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n17http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
n9http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbpedia-frhttp://fr.dbpedia.org/resource/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:List_of_antipsychotics
dbo:wikiPageWikiLink
dbr:BL-1020
Subject Item
dbr:BioLineRx
dbo:wikiPageWikiLink
dbr:BL-1020
Subject Item
dbr:BL-1020
rdf:type
yago:PsychotropicAgent104017429 yago:WikicatAntipsychotics yago:Sedative104166553 yago:Matter100020827 yago:Sedative-hypnotic104166841 yago:Tranquilizer104470232 yago:PhysicalEntity100001930 yago:CausalAgent100007347 dbo:ChemicalSubstance dbo:Drug n17:ChemicalObject yago:Substance100020090 wikidata:Q8386 yago:MajorTranquilizer103713736 yago:Agent114778436 yago:DrugOfAbuse103248958 yago:Medicine103740161 yago:Drug103247620 owl:Thing
rdfs:label
BL-1020 BL 1020
rdfs:comment
BL-1020 (perphenazine 4-aminobutanoate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia. The chemical is an ester of GABA and perphenazine; pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials. In March 2013, it went into the II/III trial phase. It has been introduced by BioLineRx, a biopharmaceutical development company. Le BL-1020 (4-aminobutanoate de perphenazine) est un antipsychotique. Il s'agit d'un ester de la perphénazine et du GABA, présentant moins d'effet indésirables que cette dernière ainsi que des effets pro-cognitifs dans les essais. Il a été développé par , une société pharmaceutique israélienne.
foaf:depiction
n9:Perphenazine_gamma-aminobutyrate.svg
dcterms:subject
dbc:D2_antagonists dbc:Piperazines dbc:Chloroarenes dbc:5-HT2A_antagonists dbc:GABA_receptor_agonists dbc:Antipsychotics
dbo:wikiPageID
38584956
dbo:wikiPageRevisionID
1120071972
dbo:wikiPageWikiLink
dbr:Schizophrenia dbr:GABA dbc:D2_antagonists dbc:Piperazines dbr:Perphenazine dbr:BioLineRx dbc:5-HT2A_antagonists dbc:Chloroarenes dbc:GABA_receptor_agonists dbc:Antipsychotics dbr:Antipsychotic
owl:sameAs
yago-res:BL-1020 dbpedia-fr:BL_1020 wikidata:Q27281832 n19:2Yof1 freebase:m.0r4w3_y
dbp:wikiPageUsesTemplate
dbt:Short_description dbt:GABAergics dbt:Nervous-system-drug-stub dbt:Reflist dbt:Antipsychotics dbt:Dopaminergics dbt:Serotonergics dbt:Fdacite dbt:Drugbox
dbo:thumbnail
n9:Perphenazine_gamma-aminobutyrate.svg?width=300
dbp:c
25
dbp:casNumber
751477
dbp:chembl
1187646
dbp:chemspiderid
9378339
dbp:cl
1
dbp:h
33
dbp:iupacName
2
dbp:n
4
dbp:o
2
dbp:pubchem
11203271
dbp:s
1
dbp:smiles
C1CNCCOCCCCN
dbp:stdinchi
1
dbp:stdinchikey
BABFYCSPNDKXRI-UHFFFAOYSA-N
dbp:unii
K1WO7H97QZ
dbp:width
250
dbo:abstract
Le BL-1020 (4-aminobutanoate de perphenazine) est un antipsychotique. Il s'agit d'un ester de la perphénazine et du GABA, présentant moins d'effet indésirables que cette dernière ainsi que des effets pro-cognitifs dans les essais. Il a été développé par , une société pharmaceutique israélienne. BL-1020 (perphenazine 4-aminobutanoate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia. The chemical is an ester of GABA and perphenazine; pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials. In March 2013, it went into the II/III trial phase. It has been introduced by BioLineRx, a biopharmaceutical development company.
prov:wasDerivedFrom
wikipedia-en:BL-1020?oldid=1120071972&ns=0
dbo:wikiPageLength
2478
dbo:casNumber
751477-01-7
dbo:chEMBL
1187646
dbo:fdaUniiCode
K1WO7H97QZ
dbo:pubchem
11203271
foaf:isPrimaryTopicOf
wikipedia-en:BL-1020
Subject Item
dbr:C25H33ClN4O2S
dbo:wikiPageWikiLink
dbr:BL-1020
dbo:wikiPageRedirects
dbr:BL-1020
Subject Item
wikipedia-en:BL-1020
foaf:primaryTopic
dbr:BL-1020